GLONGHUI July 19丨Unknown Pharmaceuticals (002581.SZ) received a regulatory letter from the Shenzhen Stock Exchange today. According to the regulatory letter, the company failed to comply with the review process in accordance with regulations and failed to disclose important matters in a timely manner. In May 2022, Hangzhou Qiangxin signed an agreement with Xiamen Weiming, a subsidiary of the company, and others, agreeing that Hangzhou Qiangxin would subscribe to Xiamen Unnamed 67.6749 million yuan in additional registered capital at a premium and obtain about 34% of the shares in Xiamen Weiming. The company failed to carry out the review procedure in accordance with the company's articles of association. Xiamen Weiming completed industrial and commercial changes on May 18, 2022, and the shareholding structure underwent major changes. The company did not promptly disclose the above matters. The company failed to disclose the litigation matters as required. In February 2023, the company listed Xiamen Unknown and Beijing Kexing as defendants and filed a lawsuit with the People's Court of Zhangdian District of Zibo City, requesting the transfer of about 26.92% of Beijing Kexing's shares under an unnamed name in Xiamen to the company. The lawsuit may have a big impact on the company's stock trading price. The company did not promptly disclose the litigation matters and did not disclose the matters in the 2022 Annual Report Correction Notice until June 15, 2023.